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Immune-checkpoint inhibitors and antitumor vaccines may produce both tumor- 
inhibitory and tumor-stimulatory effects on growing tumors depending on the stage 
of tumor growth at which treatment is initiated. These paradoxical results are not 
necessarily incompatible with current tumor immunology but they might better be 
explained assuming the involvement of the phenomenon of tumor immunostimulation. 
This phenomenon was originally postulated on the basis that the immune response 
(IR) evoked in Winn tests by strong chemical murine tumors was not linear but bipha-
sic, with strong IR producing inhibition and weak IR inducing stimulation of tumor 
growth. Herein, we extended those former observations to weak spontaneous murine 
tumors growing in pre-immunized, immune-competent and immune-depressed mice. 
Furthermore, we demonstrated that the interaction of specifical T  cells and target 
tumor cells at low stimulatory ratios enhanced the production of chemokines aimed 
to recruit macrophages at the tumor site, which, upon activation of toll-like receptor 
4 and p38 signaling pathways, would recruit and activate more macrophages and 
other inflammatory cells which would produce growth-stimulating signals leading to an 
accelerated tumor growth. On this basis, the paradoxical effects achieved by immu-
nological therapies on growing tumors could be explained depending upon where the 
therapy-induced IR stands on the biphasic IR curve at each stage of tumor growth. 
At stages where tumor growth was enhanced (medium and large-sized tumors), 
counteraction of the tumor-immunostimulatory effect with anti-inflammatory strategies 
or, more efficiently, with selective inhibitors of p38 signaling pathways enabled the 
otherwise tumor-promoting immunological strategies to produce significant inhibition 
of tumor growth.
Keywords: murine tumors, antitumor vaccines, immune-checkpoints inhibitors, tumor-immunostimulation, 
immunosurveillance
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inTrODUcTiOn
Since the classical work of Prehn and Main (1) demonstrating 
that vaccination against chemically induced murine tumors was 
feasible, there were numerous attempts to treat human tumors 
using immunological strategies. Although most of the former 
trials were disappointing, a deeper understanding of the cellular 
and molecular aspects of the immune response (IR), achieved in 
the last 20  years, prompted the development of new schedules 
of immunotherapy against cancer, including vaccines combined 
with anti-Treg or anti-myeloid-derived suppressor cells antibod-
ies and, more recently, immune-checkpoint inhibitors, such as 
antibodies against cytotoxic T  lymphocyte-antigen 4 (CTLA-4) 
or against programmed death-ligand 1 (PD-L1) (2–6).
Presumably, underlying these new schedules, there is the 
belief that the worst possible outcome for the application of 
immunological therapies is a null effect on tumor growth because 
it is assumed that there is a linear and monotonic relationship 
between the intensity of the antitumor specific IR—resulting 
from the interplay of positive (for example T cytotoxic cells) and 
negative (for example Treg cells) immunological forces—and the 
level of tumor inhibition (Figure 1A).
However, a significant body of evidence (7–9) suggests that 
the antitumor IR may be not linear but biphasic, with strong IRs 
inducing inhibition while weak ones inducing stimulation of 
tumor growth (Figure 1B). The biphasic nature of the IR curve 
on which the so-called immunostimulatory theory of cancer was 
based, entails the ambiguous suggestion that immunological 
strategies might be good therapeutic options against cancer but 
also might run a real risk of doing harm if the immunity induced 
by them is too weak to move the reaction beyond the tumor-
stimulatory part of the IR curve (8, 10).
Despite its important theoretic and therapeutic potential con-
sequences, the immunostimulatory theory of cancer has usually 
been neglected on the basis of three arguments.
First, the experiments that ultimately support this theory were 
performed using strongly immunogenic chemically induced 
murine tumors (7), which might say little about the evolution 
of the antitumor immunity during natural carcinogenesis (2, 
11–13). Second, up to date, the concept of “tumor immunostimu-
lation” lacks mechanistic support. It is now recognized that some 
effectors of the chronic non-specific inflammation contribute to 
tumorigenesis at all stages (8, 13). However, the relationship, if 
any, between this non-specific tumor-promoting effect and that 
attributed by the immunostimulatory theory of cancer to a weak 
specific IR remains to be elucidated.
Third, the immunostimulatory theory of cancer has not been 
directly tested in the context of immunotherapeutic assays against 
growing tumors.
In this work, we evaluated whether the phenomenon of 
tumor-immunostimulation is not only related to strongly 
immunogenic tumors but also to murine tumors exhibiting weak 
and undetectable immunogenicity, most of spontaneous origin, 
which have been considered the best models for most human 
cancers (11, 14, 15). We also tested other predictions of the immu-
nostimulatory theory of cancer, including therapeutic attempts 
to treat growing tumors using vaccines, immune-depressors, and 
immune-checkpoint inhibitors and explored putative mecha-
nisms underlying the phenomenon of tumor immunostimulation.
MaTerials anD MeThODs
animals
Euthymic, thymectomized at birth, and toll-like receptor 4 (TLR4)- 
KO BALB/c mice were raised in our colony. Nude BALB/c and 
NOD scid gamma (NSG) mice were purchased from Comisión 
Nacional de Energía Atómica and Instituto de Biología y 
Medicina Experimental, Argentina, respectively. Thymectomy in 
newborn mice, macrophage-depleted, and B-cell-depleted mice 
were performed as described (16, 17). Care of mice was accord-
ing to the NIH Guide and Use of Laboratory Animals, and was 
approved by the Committee for the Care and Use of Laboratory 
Animals (CICUAL) of our Institution, IMEX-CONICET, 
Academia Nacional de Medicina de Buenos Aires. Experiments 
were routinely done on euthymic mice unless otherwise stated.
Murine Tumors
MC-C: strongly immunogenic fibrosarcoma induced by the 
chemical 3-methylcholanthrene.
CEI: spontaneous undifferentiated carcinoma exhibiting 
undetectable immunogenicity.
LB: spontaneous T-lymphoid leukemia-lymphoma exhibit-
ing undetectable immunogenicity.
C7HI: medroxyprogesterone acetate-induced mammary ade-
nocarcinoma exhibiting undetectable immunogenicity.
Twelve additional tumors, mostly of spontaneous origin, that 
were used in selected experiments, are indicated in Table 1. All 
tumors were previously described (3, 16–21). Tumor dose 50 
(TD50): number of tumor cells able to grow in 50% of mice. Tumor 
volume was calculated as 0.4ab2, where a and b are the larger and 
smaller diameters, respectively (18–20). Medium was RPMI 
1640 (Gibco) supplemented as described (3). Tumor lysates, 
histological, and immunohistochemical analysis were performed 
as previously reported (3).
Winn Test
Antitumor activity of spleen cells was investigated by mixing 
them ex vivo with tumor target cells at different effector–target 
ratios. The mixtures were then inoculated by the subcutaneous 
(s.c.) route into test mice and tumor growth evaluated. The 
magnitude of tumor inhibition is considered a measure of the 
antitumor activity of spleen cells (3).
antitumor Vaccination strategies and 
Other Techniques
Tumor implantation and excision, pretreatment with X-lethally 
irradiated (LI) tumor cells, and pretreatment with dendritic cells 
incubated with tumor lysate were carried out as reported (3, 9, 16). 
Isolation of macrophages, [3H]-thymidine uptake assay, and cell-
mediated cytotoxicity against 51Cr-labeled cells were performed 
as described (3, 17, 19).
FigUre 1 | (a,B) Idealized linear (a) and biphasic (B) antitumor immune reaction curve relating the immune reactants/tumor cells ratio inoculated into test mice 
(x-axis) with tumor growth (y-axis). Letters a, b, c, d, e, f, and g indicate different ratios between immune reactants and target tumor cells. Tumor growth was 
expressed as a percentage of control tumor growth which was that observed with tumor cells alone and is represented by the horizontal dashed line. (c–e) Real 
biphasic antitumor immune response curve evaluated in Winn tests relating the immune spleen cells/tumor cells ratio inoculated into euthymic or nude test mice 
(x-axis) with tumor growth (y-axis). Data from both euthymic and nude test mice were very similar and, in consequence, were pooled. The tumor cells were 
obtained from the strongly immunogenic MC-C tumor (c), and from the tumors of undetectable immunity CEI (D) and LB (e). Spleen cells were obtained from 
normal mice or mice immunized against tumor cells (MC-C, CEI, or LB) by pretreatment with X-lethally irradiated homologous tumor cells that had been either 
untreated [full line: (▪)] or treated, before being irradiated, with an inhibitor of programmed death-ligand 1 (PD-L1) expression (JQ1, 200 nM in culture for 48 h) 
[dashed line: (▴)]. For MC-C, both curves were virtually identical, and for simplicity only the normal line was shown. Tumor growth, initiated in all cases with 1 × 105 
tumor cells, was expressed as a percentage of control tumor growth which was that observed with tumor cells alone or mixed with normal spleen cells and is 
represented by the horizontal line in 100% (for simplicity, SE of control—that was lower than 10% of the mean value, in the three tumor models—was not 
represented in the Figure). Differences were observed throughout tumor growth. By simplicity, values at day 35 of tumor growth for MC-C and CEI and at day 18 
for LB were registered in the Figure taking into account that MC-C and CEI tumors grow significantly lower than LB tumor. It is worth noting that tumor mass at 
these days predicted the survival time: the larger the tumor mass, the shorter the survival time. The curves represent the mean ± SE of five (for MC-C) and four (for 
CEI and LB) independent experiments. Each point of each experiment represents the mean of 4–6 mice. Statistics: αp < 0.05; βp < 0.02; γp < 0.01; δp < 0.001, as 
compared with control. (F–h) Expression of PDL-1. Representative experiment showing the content of surface PDL-1 in MC-C (F), CEI (g), and LB (h) tumor cells 
using flow cytometry.
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Drugs, cytokines, and chemokines
The T-immune-depressor cyclosporine A (Sandoz), the anti-
inflammatory indomethacin (Sigma-Aldrich), the selective 
p38 inhibitor SB202190 (Santa Cruz Biotechnology), and the 
pro-inflammatory thyoglycollate (Britania Laboratory, Argentina) 
were used as reported (3, 17, 22, 23).
TNF-α, IL-1β, and IL-6 were quantified using ELISA kits from 
R&D Systems. RANTES and MIP-1α chemokines that control 
TaBle 1 | Effect of immunization procedures on the growth of apparently non-immunogenic murine tumors.
Tumors TD50 (mean ± se) Method
control immunized*
conventional (#experiments) +JQ1 (#experiments)
LBa 1,093 ± 33 628 ± 123γ (6) 6,667 ± 883γ (3) 1, 2
C7-HIb 5,500 ± 800 6,200 ± 850NS (4) 1, 3
L15-Sa 1,300 ± 150 500 ± 50α (3) 1
CEIa 13,100 ± 2,400 3,150 ± 200β (3) 33,400 ± 6,400 α (2) 1, 3
T2280c 35,300 ± 2,600 22,050 ± 500γ (3) 3
CM1a 23,350 ± 4,650 23,350 ± 4,650NS (3) 1, 3
S-180a 22,700 ± 2,300 8,900 ± 1,066γ (3) 3
Fib1a 5,600 ± 150 3,200 ± 300β (2) 1
Csppa 32,000 ± 3,000 6,800 ± 500β (2) 3
CPVa 3,200 ± 500 3,200 ± 500NS (2) 3
CM2a 6,600 ± 250 1,800 ± 150α (2) 3
CM3a 30,000 ± 2,500 3,200 ± 1,000γ (2) 3
PSa 4,500 ± 100 2,200 ± 100γ (2) 1
P245a 4,600 ± 580 1,700 ± 50α (2) 1
Fib2a 8,900 ± 400 6,700 ± 400α (2) 1,3
MC-Cd (positive control) 48,000 ± 2,600 >5,000,000δ (6) >5,000,000δ (3) 1–3
aSpontaneous tumor.
bInduced in a BALB/c female mouse treated with 40 mg of medroxyprogesterone acetate (MPA) every 3 months for 1 year and thereafter maintained as an MPA-independent line.
cInduced by a novel exogenous MMTV in a BALB/c female mouse.
dInduced after implantation of a methylcholanthene pellet.
LB, L15-S, PS, and P245 are lymphomas. C7-HI, CEI, CM1, CM2, CM3, Cspp, T2280, and CPV are carcinomas. S-180, Fib1, Fib2, and MC-C are fibrosarcomas.
TD50, number of tumor cells able to grow in 50% of mice; #Experiments, number of experiments for each tumor including control and conventional immunized groups, and control, 
conventional immunized, and immunized + JQ1 groups. For each tumor and each experiment, 11–18 controls and 11–19 putatively immunized mice were used.
*Immunized.
Method: Conventional Immunization procedures.
1: pretreatment with two doses of X-lethally irradiated tumor cells 14 and 7 days before tumor challenge.
2: pretreatment with two doses of dendritic cells pulsed in vitro with tumor lysates and then inoculated in mice 14 and 7 days before tumor challenge.
3: tumor implantation and extirpation 14 days before tumor challenge.
+JQ1
Immunized with X-lethally irradiated tumor cells pretreated with an inhibitor of programmed death-ligand 1 expression (JQ1 200 nM for 48 h before being irradiated).
Statistical significance.
αp < 0.05; βp < 0.02; γp < 0.01; δp < 0.001; NS, not significant, as compared with control.
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macrophage migration were evaluated using ELISA kits from 
Pepro-Tech, following manufacturer’s recommendations.
immune-checkpoint inhibitors
JQ1 (Sigma-Aldrich), an inhibitor of PD-L1 expression was 
used in culture as described (24). Blocking anti-mouse PD-L1, 
clone 10F.9G2 and anti-mouse CTLA-4 (CD152), clone 9H10 
(BioXCell) were used as described (25).
Flow cytometry
Tumor cells were incubated with specific rat anti-mouse PD-L1, 
clone MIH5 (Ap-Biotech, Argentina) following manufacturer’s 
recommendations. Fluorescence of individual cells was measured 
in a flow cytometer (Becton Dickinson) and was analyzed with 
Cell Quest and ModFit softwares (Becton Dickinson). More 
details were given elsewhere (3).
Western Blotting
Western blotting was carried out with standard techniques as 
described (3) and analyzed by ImageQuant software. Anti-p38 
(Santa Cruz Biotechnology) and anti-β actin (Cell Signaling 
Technology) monoclonal antibodies were used. Levels of p38 
were normalized with β actin densitometry units as reported (21).
statistical analysis
Student’s t-test was used. Values were expressed as mean ± SE. 
Differences were considered to be significant whenever p value 
was ≤0.05.
resUlTs
The ir curve associated with Tumors 
Displaying Different Degrees of 
immunogenicity
The antitumor activity of spleen cells from mice putatively 
immunized against the strongly immunogenic MC-C (3) or the 
apparently non-immunogenic CEI or LB tumors (18–21) (using 
pretreatment with X-lethally irradiated homologous tumor cells 
as immunization procedures) was evaluated using Winn tests by 
mixing those spleen cells with the corresponding tumor cells at 
different spleen cells/tumor cells ratios. Then, the mixtures were 
inoculated by the s.c. route into euthymic or nude mice and 
tumor growth was determined. Tumor cells inoculated alone or 
mixed with normal spleen cells (NSCs) rendered similar results 
and served as controls. In all cases, the number of tumor cells was 
the same: 1 × 105. As shown in Figure 1C, the IR curve for MC-C 
FigUre 2 | Evaluation of tumor growth in mice displaying different degrees of immune competence. Different strains of mice were used: euthymic, thymectomized at 
birth (Tx), nude, and Nod Scid Gamma (NSG) that were challenged with different doses of tumor cells to assesses the tumor dose 50 (TD50). The tumors used were: 
MC-C, LB, CEI, and C7HI. MC-C: mean ± SE of six experiments for euthymic, Tx, and nude mice and mean ± SE of two experiments for NSG mice; LB: mean ± SE 
of six experiments for euthymic, Tx, and nude mice and mean ± SE of two experiments for NSG mice; CEI: mean ± SE of three experiments for euthymic and nude 
mice; C7HI: mean ± SE of four experiments for euthymic and nude mice. In each experiment, 12–16 mice were utilized. Statistics: αp < 0.05, γp < 0.01, δp < 0.001.
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tumor displayed both tumor-inhibitory and tumor-stimulatory 
effects at high (50/1 or 100/1) and low (0.5/1 or 1/1) spleen cells/
tumor cells ratios, respectively, and was virtually identical to the 
idealized biphasic IR curve depicted in Figure 1B. As for CEI and 
LB tumors, no inhibitory effects were detected at any point of the 
IR curve, although a significant tumor-stimulation was observed 
at high ratios (Figures 1D,E). The absence of inhibitory-mediated 
immune effects against CEI and LB tumors could be associated, 
at least in part, with the fact that both tumors (different to 
that occurred with MC-C tumor) displayed high expression of 
PD-L1 that could prevent the onset of an inhibitory antitumor 
IR (Figures 1F–H). Supporting this contention, when Winn tests 
were carried out mixing CEI or LB tumor cells with spleen cells 
collected from mice immunized with X-lethaly irradiated tumor 
cells that had been pretreated with an inhibitor of PD-L1 expres-
sion (JQ1), a significant inhibition was detected at high ratios 
while the tumor-stimulating effect moved toward lower ratios. In 
contrast, pretreatment with JQ1 did not modify the IR curve for 
MC-C tumor that displayed low content of PD-L1.
When Winn tests were performed using spleen cells immune 
to one tumor mixed with cells from another tumor, or spleen cells 
from putatively immunized nude mice, neither tumor-inhibitory 
nor tumor-stimulatory effects were observed, suggesting that 
both were specific and T-cell dependent.
effect of Pre-immunization on the growth 
of apparently non-immunogenic Tumors
The growth of 15 murine tumors, mostly of spontaneous origin, 
was analyzed in both untreated and putatively immunized 
mice. As shown in Table 1, in not a single case the conventional 
immunization procedures produced an inhibitory effect on 
tumor growth; actually, 12 out of 15 tumors were stimulated in 
the “immunized” mice. Similar to that occurred with Winn tests, 
the tumor-stimulatory effect induced by pre-immunization was 
specific and T dependent.
This suggested that the 12 stimulated tumors bore weak anti-
gens that only seemed to induce stimulatory IRs. However, when 
immunization was combined with a conspicuous inhibition of 
PD-L1 expression by immunizing mice with LI tumor cells that 
had previously been pretreated with JQ1, the TD50 of two out of 
two spontaneous tumors assayed increased significantly suggest-
ing that upon inhibition of PD-L1 the antigens of these tumors 
were also capable to induce a tumor-inhibitory IR.
As positive control of immunogenicity, Table 1 also shows that 
growth of the methylcholanthrene-induced MC-C tumor was 
strongly prevented in pre-immunized mice.
Tumor growth in Mice Displaying Different 
Degrees of immune competence
Growth of MC-C, LB, CEI, and C7HI tumors was evaluated in 
euthymic, thymectomized at birth, nude, and NSG mice which 
exhibited high, medium, low, and undetectable immune com-
petence, respectively. Immune competence was determined by 
the capacity of spleen cells to kill 51Cr-labeled tumor or normal 
allogeneic cells (not shown).
As shown in Figure 2, growth of the strongly immunogenic 
MC-C tumor that was strikingly inhibited by conventional 
pre-immunization was inversely proportional to the immune 
FigUre 3 | Role of inflammatory components in the immune-mediated tumor-stimulatory effect. (a) In vitro proliferation of 1 × 105 MC-C tumor cells alone (MCC 
alone), or admixed with anti-MC-C immune spleen cells (ISC) [obtained from mice immunized against MC-C by pretreatment with X-lethally irradiated MC-C tumor 
cells] or with normal spleen cells (NSC) at 1:1 or 50:1 ISC/MCC and NSC/MCC ratios or with inflammatory macrophages at 1:1 ratio, as evaluated by using a 18 h 
3[H]-thymidine uptake assay. Macrophages were collected from the peritoneum of mice that had received 1 ml of 3% of the pro-inflammatory thyoglycollate by the 
i.p. route, 3 days earlier. The overall 3H-thymidine uptake by attached cells was attributed to MC-C tumor cells since 3[H]-uptake by macrophages alone was 
negligible. Number of determinations per group, n = 6. Statistics: βp < 0.02 as compared with MCC alone, ISC/MCC (1:1), NSC/MCC (1:1), and NSC/MCC (50:1); 
δp < 0.001 as compared with the other groups. (B) Expression of RANTES and MIP-α. Increase in the 24h-conditioned medium of the mixture ISC/MC-C cultured at 
1:1 ratio as compared with that of NSC/MCC (1:1) and MC-C alone. The conditioned medium was obtained after culturing 24 h 5 × 106 MC-C tumor cells alone or 
mixed with 5 × 106 ISC or NSC. The number of determinations was six for RANTES and three for MIP-α. Statistics: αp < 0.05; βp < 0.02; γp < 0.01 as compared 
with ISC/MC-C (1:1). (c) Growth of MC-C tumor, 8 days after the s.c. implantation of 1 × 105 MC-C tumor cells admixed with 1 × 105 anti-MC-C ISCs (stimulatory 
mixture) (a,c) or with 1 × 105 NSCs (control) (b,d). (D) Immunohistochemistry of MC-C tumor. Increase of CD11b+/F4/80+ (a,c) and CD3+ (b,d), 8 days after the s.c. 
implantation of stimulatory mixture. Up to day 8, lymphocytes were mainly CD3+ T cells but afterward, CD20+ B220+ B cells were also observed (not shown).
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competence of the host although this relationship did not include 
NSG mice. In effect, in these extremely immune-depressed mice, 
growth of MC-C tumor was, surprisingly, similar to that attained 
in euthymic mice.
Exactly opposite results were obtained with the weakly anti-
genic CEI and LB tumors that were stimulated upon conventional 
pre-immunization. In effect, growth of both tumors was directly 
proportional to the immune competence of the host.
Finally, growth of C7HI tumor that exhibited undetectable 
antigenicity (it was neither inhibited nor stimulated upon con-
ventional pre-immunization) was similar independently of the 
immune competence of the host.
Mechanisms Underlying  
Tumor-immunostimulation
In vitro proliferation of MC-C tumor cells mixed with immune 
spleen cells (ISCs) at different spleen cell/tumor cell ratios is 
shown in Figure  3A. A striking inhibitory effect was seen at 
50/1 ratio, reproducing the in vivo observations. In contrast, no 
stimulatory effect was detected at 1/1 ratio, indicating that the 
mere interplay between ISCs and tumor cells was not enough to 
produce the tumor-immune-stimulatory effect.
Several observations suggested that inflammatory compo-
nents could play a role in the tumor-immunostimulatory effect 
observed in vivo.
First, in vitro proliferation of tumor cells was enhanced when 
they were admixed with non-specifically induced inflammatory 
macrophages (Figure 3A).
Second, the 24  h-conditioned medium of the stimulatory 
mixture (immune spleen cells/tumor cells at 1/1 ratio) displayed 
high concentration of chemokines (RANTES and MIP-1α) aimed 
to induce macrophage migration (Figure 3B).
Third, a more intense tumor-inflammatory infiltration com-
posed by CD11b+ F4/80+ macrophages and, at lesser degree, by 
FigUre 4 | Low or undetectable immune-mediated tumor-stimulatory effect in mice displaying low inflammatory responses. Evaluation of the immune response 
curve using Winn test in macrophage-depleted mice, indomethacin-treated mice, toll-like receptor 4 (TLR4)-KO mice, p38 locally deficient mice or B-cell-depleted 
mice (▪). For comparative purposes, we have, in each figure, added the control group carried out using recipient euthymic or nude mice (▫) [data were very similar 
and for simplicity, were pooled]. The dose of indomethacin (0.5 mg/kg) was diluted in 0.015 M NaCl and was inoculated in the i.p. route 1 day before tumor 
inoculation. The selective p38 inhibitor SB202190 was inoculated four consecutive days (30 μg/kg/day) at the site of tumor implantation, starting at the day of tumor 
inoculation. Normal spleen cells (NSCs) were obtained from normal mice and immune spleen cells were obtained from mice immunized against MC-C by 
pretreatment with X-lethally irradiated MC-C tumor cells. Tumor growth, initiated in all cases with 1 × 105 tumor cells, was expressed as a percentage of control 
tumor growth which was that observed in euthymic and nude test mice that received tumor cells alone or mixed with NSCs and is represented by the horizontal line 
in 100% (for simplicity, SE of control—that was lower than 10% of mean value—was not represented in the Figure). Differences were observed throughout tumor 
growth. By simplicity, values at day 35 of tumor growth were registered in the Figure. Each point of each experiment represents the mean of 4–6 mice. The curves 
represent the mean ± SE of three independent experiments. Statistics: αp < 0.05 as compared with control and 1/1 ratio; δp < 0.001 as compared with control.
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lymphocytes, were observed at the place where the stimulatory 
mixture had been implanted (Figures 3C,D, panel a,c) as com-
pared with that of tumor cells implanted alone or mixed with 
NSCs (Figures 3C,D, panel b,d).
Fourth, when Winn tests were carried out in macrophage-
depleted, indomethacin-treated, TLR4-KO or p-38-deficient test 
mice, the stimulatory effect was not observed. In B-cell-depleted 
mice, a stimulatory effect was detected but it was significantly 
lower than that observed in euthymic and nude test mice 
(Figure 4) suggesting that apart from macrophages, B cells could 
also participate—although at lesser degree than macrophages—in 
the phenomenon of tumor immunostimulation. In contrast, the 
inhibitory effect was observed indistinctly in all mice, reinforcing 
the notion that it was independent on inflammatory mediators. 
The rationale for using TLR4-KO- and p-38-deficient mice was 
based on the claim that agonists of TLR4 and activation of p38 
MAPK-signaling pathway can be important for the induction of 
the inflammation associated with neoplastic processes (26, 27).
Fifth, the expression of p38 was significantly higher in mac-
rophages collected surrounding the s.c. tumor place in mice 
receiving the stimulatory mixture than in controls, receiving 
tumor cells alone or mixed with NSCs. A similar higher expres-
sion of p38 was detected in macrophages collected from the 
peritoneum of mice that had received the stimulatory mixture 
by the i.p. route as compared with peritoneal macrophages from 
mice that had received tumor cells alone or mixed with NSCs 
(Figure 5A). This was correlated with a higher production of pro-
inflammatory TNF-α, IL-1β, and IL-6 cytokines (Figure 5B) and 
a stronger stimulatory effect on tumor growth achieved by these 
activated macrophages as compared with controls (Figure 5C).
FigUre 5 | (a) Expression of phosphorylated (p)-38 (p38) by Western blotting. Macrophages (3 × 106 cells) collected surrounding the s.c. tumor place (one 
experiment) or from the peritoneum (two experiments), 3 days after s.c. or i.p. implantation of 1 × 105 MC-C tumor cells alone (T), or mixed with normal spleen cells 
(NSCs) at 1/1 ratio [N:T (1:1)], with immune spleen cells (ISCs) at 1/1 ratio [I:T (1:1)] or with ISCs at 1/1 ratio plus the p38 inhibitor (days 0–3, 30 μg/kg/day) at the 
place of tumor inoculum [I:T (1:1) + α-p38]. Intraperitoneal macrophages from normal mice were used as negative controls of p38 expression (Ct−). Pervanadate 
(OVAN) was used as positive phosphorylation controls (Ct+). Macrophages collected from mice that received 1 ml of 3% thyoglycollate (tg) by the i.p. route, 3 days 
earlier, served as control of non-specific inflammation. At the left, a representative experiment is shown. At the right, histograms show levels of p38 in the different 
groups, normalized with beta-actin densitometric units, representing the mean ± SE of three independent experiments. NSCs were obtained from normal mice and 
ISCs were obtained from mice immunized against MC-C tumor by pretreatment with X-lethally irradiated MC-C tumor cells. Statistics: βp < 0.02; γp < 0.01; 
δp < 0.001 as compared with the I:T (1:1) group. (B) Expression of TNF-α, IL-1β, and IL-6 pro-inflammatory cytokines in the 24-h conditioned medium of 
macrophages collected from the peritoneum of mice that had received, 3 days before, an i.p. inoculation of 1 × 105 MC-C tumor cells alone or mixed with 
stimulatory mixture at 1/1 ratio [I:T (1:1)]. Statistics: control versus I:T (1:1); βp < 0.02; γp < 0.01; mean ± SE of three experiments. (c) Effect of macrophages 
activated by the stimulatory mixture on the growth of MC-C tumor. Euthymic test mice received by the s.c. route 1 × 105 MC-C tumor cells mixed with peritoneal 
macrophages (1 × 105) of mice that had received i.p. 3 days earlier the stimulatory mixture [at 1/1 ratio, (●), n = 6]. As a control of non-specific inflammation, MC-C 
tumor cells were mixed with peritoneal macrophages of mice that received 3% thyoglycollate (tg) [(▫); n = 4, i.p. 3 days earlier]. The control groups (○) were, mice 
that received MC-C tumor cells alone (1 × 105, n = 4), or mixed with macrophages collected from mice that had received the normal mixture (at 1/1 ratio, n = 4), or 
none (n = 4). The data of the control groups were almost identical and were pooled. Tumor growth was registered in all groups. Statistics: Stimulatory mixture group 
(●) versus Control groups (○): αp < 0.05; γp < 0.01; and δp < 0.001; Stimulatory mixture group (●) versus tg group (▫): αp < 0.05 and γp < 0.01 and tg group (▫) 
versus control groups (○): βp < 0.02.
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Therapeutic antitumor immunological 
schedules: Benefits and risks
Different antitumor immunological schedules were attempted 
therapeutically against two murine tumors that had already 
started their growth, the strongly immunogenic MC-C (low 
PD-L1 content) and the weakly antigenic LB (high PD-L1 
content).
Vaccines and Immune-Depressors
Antitumor vaccines inhibited MC-C tumor growth when they 
faced incipient tumors. Afterward, the vaccines produced null or 
stimulatory effects on tumor growth (Figure 6A).
In contrast, the vaccines induced an accelerated LB tumor 
growth when they faced incipient tumors. Afterward, neither 
inhibitory nor stimulatory effects were observed.
In both tumor models, the immune-depressor cyclosporine 
A produced opposite effects to those observed with the vaccines, 
although both tumor-inhibitory and tumor-stimulatory effects 
were rather modest.
Immune-Checkpoint Inhibitors
A conspicuous inhibition on MC-C tumor was observed when 
an anti-CTLA-4 treatment was initiated at early stages of tumor 
growth; however, as tumor grew, tumor-stimulatory effects were 
observed (Figure 6B). On the other hand, no effect was achieved 
at any stage of MC-C tumor growth when anti-PDL-1 antibodies 
were used.
In contrast, an accelerated growth of LB tumor was observed 
when an anti-CTLA-4 treatment was initiated at early stages of 
tumor growth; afterward, no effect was detected. On the other hand, 
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a conspicuous inhibition of LB tumor was achieved with anti-PDL1 
antibodies although it was restricted to incipient tumors only.
The administration of anti-CTLA-4 together with anti-PD-L1 
antibodies slightly improved the antitumor effects of each sepa-
rately, but, again, only when small tumors were concerned.
Counteraction of the Tumor-Immunostimulatory 
Effects
The administration of indomethacin or, more efficiently, SB 202190 
(selective p38-inhibitor), counteracted the tumor-stimulatory 
effects achieved by antitumor vaccines or immune-checkpoint 
inhibitors and produced a significant inhibition of medium- and 
large-sized established tumors in both the strongly immunogenic 
and the weakly antigenic models (Figure 6C). Indomethacin or 
SB202190 alone did not produce any effect.
DiscUssiOn
Immunological strategies have been claimed to be promissory for 
the treatment of cancer because they could, at least theoretically, 
circumvent the limitations of conventional non-specific antitu-
mor therapies (2).
However, to date, most attempts to cause an immuno-
logically mediated regression of animal and human tumors, once 
FigUre 6 | Continued
FigUre 6 | Therapeutic antitumor immunological schedules. (a) Vaccines and Immune-depressors. Tumor growth was initiated at day 0 with a s.c. inoculum of 
1 × 105 MC-C or LB tumor cells in the right flank. Afterward, at selected times after tumor inoculation, different groups of mice received in the left flank an antitumor 
vaccine [4 × 106 X-lethally irradiated tumor cells or 3 × 105 dendritic cells loaded with tumor lysate (both vaccines rendered similar results and in consequence their 
data were pooled)] or the immune-depressor Cyclosporine A [inoculated i.p. every day (15 mg/kg/day) starting at day 3 or 18 of MC-C tumor growth or at day 1 or 
10 of LB tumor growth]. The group of mice that did not receive any treatment served as control. The Figure shows representative experiments (one for MC-C and 
one for LB) out of four experiments for MC-C and three experiments for LB that rendered similar results. Six mice per group were utilized in the representative 
experiments and data were expressed as mean (mm3) ± SE of tumor volume. Statistics: Differences versus control group: αp < 0.05; βp < 0.02; γp < 0.01; 
δp < 0.001. (B) Immune-checkpoint inhibitors. Tumor growth was initiated at day 0 with a s.c. inoculum of 1 × 105 MC-C or LB tumor cells in the right flank. 
Afterward, different groups of mice received blocking anti-cytotoxic T lymphocyte-antigen 4 (CTLA-4) (inoculated i.p. three times a week), blocking anti-programmed 
death-ligand 1 (PD-L1) (inoculated i.p. for 13 consecutive days) or both blocking anti-CTLA-4 plus blocking anti-PD-L, starting at selected times (indicated in the 
Figure) after tumor inoculation. The group of tumor-bearing mice that did not receive any treatment served as control. The Figure shows representative experiments 
(one for MC-C and one for LB) out of two experiments for MC-C and three experiments for LB that rendered similar results. Four to six mice per group were utilized 
in the representative experiments and data were expressed as mean (mm3) ± SE of tumor volume. Statistics: Differences versus control group: αp < 0.05; γp < 0.01; 
δp < 0.001. (c) Counteraction of the tumor-immunostimulatory effects observed on well-established tumors (well-established meaning solid tumors that are 
≥400 mm3). MC-C tumor: tumor growth was initiated at day 0 with a s.c. inoculum of 1 × 105 MC-C tumor cells in the right flank. At day 18 of tumor growth, 
different groups of mice received an antitumor vaccine alone (X-irradiated tumor cells or dendritic cells loaded with tumor lysate), an antitumor vaccine plus 
indomethacin, anti-CTLA-4 alone, anti-CTLA-4 plus indomethacin, or anti-CTLA-4 plus SB202190. Anti-CTLA-4 was inoculated i.p. three times a week starting at 
day 18 of tumor growth. Indomethacin (0.5 mg/kg) was inoculated i.p. once at day 17. SB202190 (30 μg/kg/day) was inoculated i.p. for four consecutive days 
starting at day 18 of tumor growth. The group of tumor-bearing mice that did not receive any treatment served as control. LB tumor: tumor growth was initiated at 
day 0 with a s.c. inoculum of 1 × 105 LB tumor cells in the right flank. At day 1 of tumor growth, two groups of mice received an antitumor vaccine alone 
(X-irradiated tumor cells or dendritic cells loaded with tumor lysate), or the antitumor vaccine plus indomethacin (inoculated i.p. at day 0). At day 10 of tumor growth 
other groups of mice received anti-PD-L1 alone (inoculated i.p. for 13 consecutive days starting at day 10 of tumor growth), or in combination with indomethacin 
(inoculated i.p. at day 9 of tumor growth) or with SB202190 (inoculated i.p. for four consecutive days starting at day 10 of tumor growth). The group of tumor-
bearing mice that did not receive any treatment served as control. The Figure shows representative experiments (one for MC-C and one for LB) out of three 
experiments for MC-C and three experiments for LB that rendered similar results. Four to six mice per group were utilized in the representative experiments and data 
were expressed as mean (mm3) ± SE of tumor volume. Statistics: differences versus control group: αp < 0.05; βp < 0.02; γp < 0.01; δp < 0.001. Difference between 
anti-CTLA-4 plus indomethacin group versus anti-CTLA-4 plus SB202190 group: *p < 0.02. Difference between anti-PD-L1 plus indomethacin group versus 
anti-PD-L1 plus SB202190 group: **p < 0.05. y-axis: tumor volume (mm3). (a,B) x-axis: days of tumor growth at the onset of treatment. For MC-C tumor, days 3, 7, 
12, 18, and 28 of tumor growth corresponded to tumor volumes of <10, 50, 250, 600, and 1,500 mm3, respectively. For LB tumor, days 1, 6, and 10 of tumor 
growth corresponded to tumor volumes of <10, 300, and 700 mm3, respectively. (c) x-axis: treatments. Differences were observed throughout tumor growth. By 
simplicity, values at day 35 of MC-C tumor growth and at day 18 of LB tumor growth were registered in the figures taking into account that MC-C tumor grows 
significantly slower than LB.
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well-established (28) have not been very successful (3, 8, 28, 29). 
This has usually been attributed to the putative weak antigenicity 
of spontaneous tumors (11, 15, 16, 28) and/or to the emergence of 
tumor- associated negative immune-regulatory mechanisms (3, 
30, 31). Another alternative, suggested by the immunostimulatory 
theory of cancer, postulates that current immunological therapies 
directed against naturally arisen tumors usually produce weak 
antitumor IRs that would promote rather than inhibit tumor 
growth (7, 10) which, in turn, was inspired by the possibility 
that a weak IR to a fetus (32) may be beneficial for fetal survival. 
However, the immunostimulatory theory of cancer and many 
experiments that seemed to support it (7, 8), were developed 
when our understanding of the immune system was limited, and 
up to date, the mechanisms underlying that tumor-stimulatory 
effect have not yet been elucidated (8).
In this work, we have extended the empirical basis of the 
immunostimulatory theory of cancer suggesting that the IR 
curve evoked by most murine tumors is not linear but biphasic. 
This contention was supported by classical immunological 
assays and by the demonstration that many spontaneous murine 
tumors, formerly claimed to be non-antigenic (11), grow faster 
in pre-immunized hosts and more slowly when transplanted 
in immunocompromised mice. To explain these observations, 
we only must assume that many “non-immunogenic” tumors 
are in fact weakly antigenic when transplanted in conventional 
mice, and generate a stimulatory IR that is placed to the left in 
the biphasic IR curve (see Figure  1B), for example in “b.” In 
that case, any conventional vaccination, aimed to enhance that 
antitumor IR could move the reaction toward “c,” producing 
accelerated tumor growth although more stringent strategies 
such as immune-checkpoint inhibitors could, upon certain 
circumstances, move the IR up to the inhibitory zone of the IR 
curve. Others have already observed similar tumor-enhancing 
effects after conventional pre-immunization against spontaneous 
murine tumors (11, 33). Reciprocally, when they were trans-
planted in immunocompromised mice, the IR could be moved 
toward “a,” where tumor growth would be retarded. The relatively 
few cases of spontaneous tumors that were neither inhibited nor 
stimulated by pre-immunization and/or immunodepression can 
also be explained assuming that the IR evoked by them is placed 
between “0” and “a” where no perceptible effects by altering the 
immunological state of the host could be anticipated.
In contrast, the strongly immunogenic methylcholanthrene-
induced murine tumor utilized in this work, as well as other 
strongly immunogenic murine tumors reported in the literature 
(3, 7, 20, 29), were inhibited by pre-immunization and grew 
faster in immune-depressed mice. This behavior can be explained 
assuming that the IR mounted against strongly immunogenic 
tumors inoculated in conventional mice, is probably placed to the 
right in the IR curve, for example near “f.” In that case, a preven-
tive vaccination will move the reaction toward “g” (to the right), 
which would produce stronger tumor inhibition. Reciprocally, 
in immunocompromised mice, the IR will be moved to the left, 
toward “e” or “d,” producing faster tumor growth. However, when 
the immune competence of mice was extremely low, as occurred 
in NSG mice (34), tumor growth returned to values observed in 
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euthymic mice which can be elucidated assuming that, in that case, 
the IR moved far to the left surpassing the curve hump toward “a.”
The above considerations can help overcome a major obstacle 
for the acceptation of the immunostimulatory theory of cancer 
namely the fact that it relativizes the currently accepted premise 
that states that, in the natural history of all cancers, the earliest 
antitumor IR is inhibitory. This claim is based on the fact that the 
overall incidence of cancer is augmented in immunosuppressed 
individuals. However, this overall incidence is supported by a 
striking increased incidence of only a few tumor types, while 
the incidence of most other tumors is marginally augmented, 
not augmented or actually lowered upon immune-depression, 
in both animals and men (8, 12, 13, 35–39). Some authors have 
questioned this conclusion showing that some new developed 
molecularly defined murine models of immunodeficiency such 
as GM-CSF/IFN-γ−/− doubly deficient and GM-CSF/IL-3/IFN-
γ−/− triply deficient mice, display a higher incidence of many 
tumor types apparently supporting the immunosurveillance 
predictions. However, these models are also highly susceptible to 
bacterial infection displaying acute and chronic inflammation in 
many organs. The fact that tumor development can be prevented 
by maintaining the mice on broad-spectrum antibiotics from 
birth, suggests that the state of chronic inflammation induced by 
the infections, rather than a putative depression of specific anti-
tumor IRs would be the main condition for cancer development 
(37). Further, NSG, that is one of the most immune-deficient 
strain of inbred laboratory mice described to date display lower—
instead higher—incidence of spontaneous tumors than other less 
immune-deficient mice (40).
The contention that the incidence of most tumors is not 
significantly augmented and, in fact, in some cases, is lowered by 
immune-depression might be explained assuming that, in most 
cases, the earliest IR evoked during the natural history of car-
cinogenesis is similar to that observed during the experimental 
transplantation of spontaneous murine tumors, that is, it is placed 
to the left of the biphasic IR curve, between “0” and “a” or between 
“a” and “c.” For example, the much more frequent lymphoglan-
dular complexes associated with the rectum, in comparison to 
that associated with elsewhere in the colon, led Stewart to suggest 
that immunostimulation of cancers may be greater in the rectum 
than in the rest of the bowel and that the lower incidence of rectal 
malignancies in immunodepressed patients may, therefore, be the 
result of the loss of much of this normal tumor-stimulation (38).
Furthermore, the theory might also account even for the cases 
in which immunodepression strikingly enhance the incidence 
of highly immunogenic methylcholanthene-induced sarcomas 
in the mouse or Kaposi’s sarcoma and skin and hematological 
malignancies in the man. At first sight, the behavior of these 
tumors seems to be only compatible with the immunosurveil-
lance theory. However, can one really be sure that an immuno-
depression diminishes an initial inhibitory response rather than 
augments a stimulatory one? If the latter possibility were true, the 
earliest IR directed to these nascent tumors might also be consid-
ered as stimulatory. Two lines of observations support this con-
tention. First, methylcholanthrene-induced sarcomas are usually 
strongly immunogenic when tested in syngeneic mice, but fail 
to show immunogenicity in the very mouse in which the tumor 
had originated, unless the animal is hyper-immunized (41–43); 
instead, they seem to be stimulated (41, 44). If even these tumors, 
paradigms of strong immunogenicity, are immune-stimulated 
rather than immune-inhibited when growing in their autochtho-
nous hosts, it seems to us unlikely that in the early evolution of 
the same tumors, the incipient and, therefore, weaker antitumor 
IR could be inhibitory. In the second place, Kaposi’s sarcoma, a 
prototypical lesion in AIDS patients, commonly “flares” during 
the period of immune recovery while the AIDS is being treated. 
This suggests that the tumor grows best when the immune capac-
ity of the patients is still impaired, but not too impaired (45).
The immunoediting hypothesis (13) extends the immuno-
surveillance theory suggesting that the immune system not only 
controls the origin of tumors but also sculpts their antigenic 
profiles, by negatively selecting tumor cells that are poorly or non-
antigenic or that are able to subvert the IR of the host. However, if 
the early IR were not inhibitory but stimulatory, clones with low 
antigenicity, displaying the ability to induce a tumor-stimulating 
IR would be positively selected. In some cases (46), this reaction 
could continue to stimulate the growth of such tumors long 
after their inception. In other cases, the initial weak stimulatory 
response could, as it develops, become inhibitory. In these cases, 
the initial “S” (stimulation) of the immunostimulatory theory of 
cancer should, as it was previously suggested (47), be integrated 
with the three “Es” (elimination, equilibrium, escape) of the 
immunoediting one.
Another obstacle for the acceptation of the immunostimula-
tory theory of cancer has been its lack of mechanistic support. 
In this work we suggested that the interaction between immune 
spleen T  cells with tumor cells at a low ratio (mimicking a 
weak antitumor-IR), would produce a significantly higher 
concentration of chemokines (such as RANTES and MIP-
1α) aimed to attract macrophages at the tumor site, than that 
produced by tumor cells alone or mixed with NSCs. In turn, 
these macrophages, upon activation of TLR4 and p38 signaling 
pathways would release pro-inflammatory mediators that would 
recruit and activate more macrophages and other inflammatory 
cells—for example B  cells, as our experiments and a previous 
work (47) have suggested—at the tumor site that might produce 
tumor-growth-stimulating signals leading to an accelerated 
tumor growth. A rather similar mechanism has recently been 
proposed to explain how a T-cell dependent adaptive IR can 
promote the progression of pre-neoplasia to cancer in an estab-
lished mouse model of prostate cancer (48). In fact, the stages of 
solid tumors in which tumor cells begin their exponential growth 
and the antitumor IR is significantly impaired or weakened by 
not yet fully understood tumor-associated mechanisms (3, 30), 
are characterized by a chronic inflammatory condition with 
moderately elevated levels of NF-κB activity in both tumor and 
inflammatory cells. The notion that such moderate and constitu-
tive activity of NF-κB exerts a pro-tumorigenic effect is suggested 
by the fact that patients with chronic inflammatory diseases have 
significantly higher risks for cancer than the general population 
(49). In contrast, acute inflammatory processes involving full 
activation of NF-κB, produce antitumor effects since are usually 
accompanied by a high activity of cytotoxic immune cells against 
cancer cells (49).
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The arguments presented herein have not merely theoretic 
value but also practical consequences, since they could explain 
the paradoxical effects of different immunological strategies on 
the treatment of established tumors in both experimental (9, 
10) and clinical settings (47). In effect, these paradoxical effects 
might be understood depending upon where the system stands 
on the biphasic IR curve at each stage of tumor growth, which in 
turn, would depend upon the antigenic profile of the tumor, the 
immunogenic strength of the immunotherapeutic schedule, and 
the immunological state of the host (3, 9).
In our experiments, both antitumor vaccines and immune-
checkpoint inhibitors were effective to restrain tumor growth, 
although only when they faced incipient or small-sized tumors. 
Afterward, as tumor became larger, and the IR was expected to 
be moved to the left in the IR curve—because during tumor pro-
gression tumor cells usually grow faster than immune reactants 
(9)—null and stimulatory effects on tumor growth were observed.
At the time when immunostimulation was evident, some 
form of mitigation of immunity was therapeutically advanta-
geous although the beneficial effects were rather modest. In our 
hands, the most significant inhibition of medium- and large-sized 
chemically induced and spontaneous tumors was accomplished 
by combining vaccines or immune-checkpoint inhibitors with 
strategies aimed to counteract tumor immunostimulation. We 
achieved this aim with the use of conventional anti-inflammatory 
agents and, more efficiently, with a selective p38 inhibitor sup-
porting the suggestion that a p38-dependent inflammatory reac-
tion underlies the phenomenon of tumor immunostimulation. In 
clinical trials for advanced cancer, immune-checkpoint inhibitors 
and other immunological approaches only demonstrated benefi-
cial effects in a small cluster of patients (2, 30, 47). We suggest that 
these patients might for some reason have been unable to mount 
a significant inflammatory response preventing the emergence of 
a state of tumor immunostimulation. The observation presented 
in this work that the immunostimulatory arm of the IR curve 
is not observed in Winn assays carried out in test mice that 
cannot mount an inflammatory response, seems to support that 
suggestion. Similarly, the low incidence of spontaneous tumors 
exhibited by NSG mice might be attributed to their low ability 
to generate tumor immunostimulation associated with their 
defective capacity to mount both a specific antitumor IR and a 
macrophage-dependent inflammatory response (34). In fact, the 
therapeutic antitumor success (when it occurred) of BET (bromo-
domain and extra-terminal motif) inhibitors could be attributed, 
at least in part, to their ability to impair macrophage-mediated 
inflammation (50). A deeper understanding of the phenomenon 
of tumor immunostimulation together with the analysis of the 
genetic profile of tumor antigens aimed to distinguish between 
those that could induce strong, weak or tumor-stimulatory IRs 
could help to design improved immune-therapeutic approaches 
to cancer and eventually achieve the still elusive goal of eradicat-
ing well-established tumors by immunological means.
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